Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research
03 June 2024 - 10:00PM
Business Wire
The Thermo Scientific™ Stellar™ mass
spectrometer combines speed and sensitivity to advance precision
medicine
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in
serving science, today unveiled the Thermo Scientific™ Stellar™
mass spectrometer (MS), a new solution that combines fast
throughput, high sensitivity, and ease of use to allow researchers
to advance their translational omics research and make breakthrough
discoveries more efficiently.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240603406362/en/
The Thermo Scientific Stellar mass
spectrometer combines speed and sensitivity to advance precision
medicine (Photo: Business Wire)
The Stellar MS powers translational research, the conversion of
basic science discoveries into clinical applications with the
ultimate goal of improving human health, as it streamlines the
verification of proteins and metabolites of clinical interest.
Complementing the Thermo Scientific Orbitrap™ Astral™ MS, Stellar
MS completes a key piece of the translational research workflow.
The Orbitrap Astral MS is ideal for discovering new biomarkers and
the Stellar MS connects these discoveries to clinical research,
providing verification of all biomarkers that matter, including
peptides, metabolites, and lipids.
This workflow includes third-party software support via Thermo
Scientific Ardia™ platform and high throughput liquid
chromatography separation with the Thermo Scientific Vanquish™ Neo
ultra-high performance liquid chromatography (UHPLC) system Tandem
Direct Injection workflow, enabling significant time savings.
Translational scientists can now create new workflows in just days
rather than weeks using existing technology, ultimately delivering
faster study completion that supports significantly improved
productivity.
Compared to traditional technologies, Stellar MS achieves 10X
the quantitative sensitivity while analyzing five times more
compounds for proteomics, metabolomics, and lipidomics. Researchers
can now achieve quantitative productivity and gain insights on a
broader range of compounds which were previously impossible.
“Our industry-leading instruments will accelerate the promise of
precision medicine and bolster essential translational research
that will help improve human health,” said John Lesica, president,
chromatography and mass spectrometry, Thermo Fisher Scientific.
“Equipping our customers with the ability to discover and validate
insights at unprecedented scale can offer biological insights into
disease mechanisms that improve clinical research outcomes and help
develop personalized therapies far faster than previously
possible.”
Thermo Fisher will showcase the Stellar MS at the American
Society for Mass Spectrometry (ASMS) annual conference from June
2-6, 2024, in Anaheim, California. The Stellar and Orbitrap Astral
mass spectrometers, together with additional new products being
introduced at ASMS, will be on display, showcasing how scientific
changemakers are shaping the future of human health from compounds
to clinics with these technologies.
For more information, please visit
www.thermofisher.com/ASMS.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with annual revenue of over $40 billion. Our Mission is to
enable our customers to make the world healthier, cleaner and
safer. Whether our customers are accelerating life sciences
research, solving complex analytical challenges, increasing
productivity in their laboratories, improving patient health
through diagnostics or the development and manufacture of
life-changing therapies, we are here to support them. Our global
team delivers an unrivaled combination of innovative technologies,
purchasing convenience and pharmaceutical services through our
industry-leading brands, including Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services,
Patheon and PPD. For more information, please visit
www.thermofisher.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240603406362/en/
Media Contact Information: Laura Bright
laura.bright@thermofisher.com
Investor Contact Information: Rafael Tejada
rafael.tejada@thermofisher.com
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Sep 2023 to Sep 2024